Lung & Respiratory Disease Clinical Trials Update: Week 40, 2026

Published October 2, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

This ongoing study is exploring how a new triple combination therapy affects people with cystic fibrosis, including children and adults, in everyday life. By following 206 participants in Ireland and the UK over several years, the research aims to show how this treatment impacts lung and digestive health outside of controlled trial settings. This information could help families and healthcare providers better understand the long-term benefits and challenges of this therapy in managing cystic fibrosis.

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial

This Phase 2 trial is testing tirzepatide, a medication that helps with weight loss, to see if it can improve obstructive sleep apnea symptoms better than the standard continuous positive airway pressure (CPAP) machines. With 256 adults planned to join in Australia, the study may offer a new treatment option that could be easier for some people to use, potentially improving sleep quality and overall health for those with sleep apnea and obesity.

N-WATCH: Nottingham Wheeze Assessment in Tidal Children

This study is evaluating a small, user-friendly device called N-Tidal that helps children with asthma and their families monitor lung function at home. By making it easier to detect early signs of worsening asthma, the device could lead to quicker management decisions and fewer emergency visits. Recruiting in the United Kingdom, the research will help plan larger future trials to confirm how helpful this technology might be in daily asthma care.

Nebulized Ketamine for Severe Asthma Attacks in Children

This upcoming Phase 2 trial will test nebulized ketamine as a potential treatment for severe asthma attacks in children aged 1 to 13 years. If successful, this option might improve breathing and reduce hospital stays for children who do not respond well to current asthma treatments. The study is preparing to enroll 60 children in Oman and could provide an important new tool for managing severe asthma in young patients.

Smoking Cessation Intervention Including Health Navigators to Address Unmet Social Needs of Parents Who Smoke

This study is combining smoking cessation support with health navigator assistance to help parents who smoke and face social challenges. By addressing both quitting and social needs, the program aims to help parents stop smoking and reduce their children's exposure to secondhand smoke. Recruiting in pediatric clinics across Canada, the trial plans to enroll 1000 participants to better understand how to support families in quitting tobacco.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.